Filtered By:
Drug: Metformin

This page shows you your search results in order of relevance. This is page number 6.

Order by Relevance | Date

Total 2318 results found since Jan 2013.

Designing novel therapies against sarcomas in the era of personalized medicine and economic crisis.
Abstract Drug "repurposing" is the process of finding new therapeutic indications for existing drugs, and can be considered as a more efficient and realistic strategy for the design of therapies against rare diseases than the current efforts to develop targeted-drugs. In this review, we explore the difficulties related to the identification and development of tailored therapies for individual patients with sarcomas, which are relatively rare diseases characterized by an extreme genetic and histologic variability. Overall, sarcomas comprise about 1% of all adult tumors and 10% of pediatric cancers. They are convent...
Source: Current Pharmaceutical Design - February 4, 2013 Category: Drugs & Pharmacology Authors: Manara MC, Garofalo C, Ferrari S, Belfiore A, Scotlandi K Tags: Curr Pharm Des Source Type: research

A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and β‐cell function: the triple oral therapy
ConclusionsSitagliptin should be preferred to glibenclamide as an addition to the metformin + pioglitazone combination for its better protection of β‐cell secretion and its neutral effect on body weight.© 2013 The Authors. Diabetic Medicine © 2013 Diabetes UK
Source: Diabetic Medicine - February 18, 2013 Category: Endocrinology Authors: G. Derosa, A. F. G. Cicero, I. G. Franzetti, F. Querci, A. Carbone, M. N. Piccinni, A. D'Angelo, E. Fogari, P. Maffioli Tags: Research Article Source Type: research

Metformin may not reduce cardiovascular risk or all-cause mortality
Commentary on: Boussageon R, Supper I, Bejan-Angoulvant T, et al.. Reappraisal of metformin efficacy in the treatment of Type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med 2012;9:268–82. Context The treatment of hyperglycaemia is considered as one of the tools for preventing cardiovascular disease in Type 1 and Type 2 diabetic (T2D) patients.1 2 Metformin is recommended as the first-line drug for T2D by most international guidelines (IDF.2005. http://www.idf.org, 2007. http://www.aace.com, http://www.diabetesjournals.org, http://www.nice.org.uk/CG66). The preference for metformin over other av...
Source: Evidence-Based Medicine - March 19, 2013 Category: Internal Medicine Authors: Monami, M. Tags: Geriatric medicine, Clinical trials (epidemiology), Epidemiologic studies, Drugs: cardiovascular system, Stroke, Hypertension, Diet, Ischaemic heart disease, Diabetes Online articles Source Type: research

Baylor College of Medicine receives sizable grant from Komen for cancer research
Researchers from Baylor College of Medicine in Houston received $960,000 from Susan G. Komen for the Cure to advance breast cancer research. Dr. Sao Jiralerspong, assistant professor in the Lester and Sue Breast Center at BCM, was awarded a $450,000 grant to explore the lab potential of metformin, a diabetes drug, to reduce the threat that ductal carcinoma in situ will spread and develop into a more invasive type of cancer. Dr. Melissa Bondy, professor of pediatrics in hematology and oncology,…
Source: bizjournals.com Health Care:Hospitals headlines - August 1, 2013 Category: Hospital Management Authors: Bayan Raji Source Type: research

Case 23-2013: A 54-Year-Old Woman with Metformin Toxicity
New England Journal of Medicine, Volume 369, Issue 18, Page 1767-1769, October 2013.
Source: New England Journal of Medicine - October 30, 2013 Category: Internal Medicine Tags: article Source Type: research

Metformin trims fats to restore insulin sensitivity
Nature Medicine 19, 1570 (2013). doi:10.1038/nm.3414 Author: Reuben J Shaw Despite metformin being one of the most commonly prescribed drugs for the treatment of diabetes, how it elicits its therapeutic effects has remained mysterious. A new study in mice shows that inhibitory phosphorylation of acetyl-coA carboxylases Acc1 and Acc2 by the AMP-activated protein kinase (AMPK) is essential for the ability of metformin to improve insulin sensitivity and lower blood glucose in obesity (pages 1649–1654).
Source: Nature Medicine - December 5, 2013 Category: Journals (General) Authors: Reuben J Shaw Tags: News and Views Source Type: research

Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin
Nature Medicine 19, 1649 (2013). doi:10.1038/nm.3372 Authors: Morgan D Fullerton, Sandra Galic, Katarina Marcinko, Sarah Sikkema, Thomas Pulinilkunnil, Zhi-Ping Chen, Hayley M O'Neill, Rebecca J Ford, Rengasamy Palanivel, Matthew O'Brien, D Grahame Hardie, S Lance Macaulay, Jonathan D Schertzer, Jason R B Dyck, Bryce J van Denderen, Bruce E Kemp & Gregory R Steinberg The obesity epidemic has led to an increased incidence of nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes. AMP-activated protein kinase (Ampk) regulates energy homeostasis and is activated by cellular stress, hormones and the widely pr...
Source: Nature Medicine - November 3, 2013 Category: Journals (General) Authors: Morgan D FullertonSandra GalicKatarina MarcinkoSarah SikkemaThomas PulinilkunnilZhi-Ping ChenHayley M O'NeillRebecca J FordRengasamy PalanivelMatthew O'BrienD Grahame HardieS Lance MacaulayJonathan D SchertzerJason R B DyckBryce J van DenderenBruce E Kemp Tags: Letter Source Type: research

Association of B12 deficiency and clinical neuropathy with metformin use in type 2 diabetes patients
Conclusion: Metformin use is associated with vitamin B12 deficiency and clinical neuropathy in Type 2 diabetes patients.
Source: Journal of Postgraduate Medicine - December 17, 2013 Category: Internal Medicine Authors: AK SinghA KumarD KarmakarRK Jha Source Type: research

Do geriatrics require dose titration for antidiabetic agents?
Conclusion: A substantial dose reduction of glibenclamide (25%), gliclazide (25%), glimepiride (22%), and metformin (5%) in geriatrics compared to nongeriatrics was observed. Smaller dosage formulations like 0.75 mg glibenclamide, 0.5 mg glimepiride, 20 mg gliclazide, and 250 mg metformin may be of value in geriatric diabetic practice.
Source: Journal of Postgraduate Medicine - December 17, 2013 Category: Internal Medicine Authors: R ShastryP AdhikariA KamathM ChowtaS UllalMRSM Pai Source Type: research

Comment: Association of B12 deficiency and clinical neuropathy with metformin use in type 2 diabetes patients
VN ShahJournal of Postgraduate Medicine 2014 60(1):95-95
Source: Journal of Postgraduate Medicine - March 14, 2014 Category: Internal Medicine Authors: VN Shah Source Type: research

Comment on: Association of B12 deficiency and clinical neuropathy with metformin use in type 2 diabetes patients
MN Chowta, G TiwaryJournal of Postgraduate Medicine 2014 60(1):96-97
Source: Journal of Postgraduate Medicine - March 14, 2014 Category: Internal Medicine Authors: MN ChowtaG Tiwary Source Type: research

The potential role of GLUT4 transporters and insulin receptors in the hypoglycaemic activity of Ficus lutea acetone leaf extract
Conclusion: Only F. lutea possessed substantial in vitro activity related to glucose metabolism. Based on the effect produced in the various cell types, F. lutea also appears to be a partial agonist/antagonist of the insulin cell membrane receptor. While the clinical effectiveness of F. lutea is not known, this plant species does possess the ability to modify glucose metabolism.
Source: BMC Complementary and Alternative Medicine - July 28, 2014 Category: Complementary Medicine Authors: Oyinlola OlaokunLyndy McGawMaurice AwouafackJacobus EloffVinny Naidoo Source Type: research

The Target of Metformin in Type 2 Diabetes
New England Journal of Medicine, Volume 371, Issue 16, Page 1547-1548, October 2014.
Source: New England Journal of Medicine - October 15, 2014 Category: Internal Medicine Tags: article Source Type: research

Metformin in Cancer Treatment and Prevention.
This article outlines the link between metformin and cancer, the potential for metformin in oncology, and limitations of currently available evidence. Expected final online publication date for the Annual Review of Medicine Volume 66 is January 14, 2015. Please see http://www.annualreviews.org/catalog/pubdates.aspx for revised estimates. PMID: 25386929 [PubMed - as supplied by publisher]
Source: Annual Review of Medicine - November 6, 2014 Category: Journals (General) Authors: Morales DR, Morris AD Tags: Annu Rev Med Source Type: research

Stratified medicine for the use of anti‐diabetic medication in treatment of type 2 diabetes and cancer: where do we go from here?
This article is protected by copyright. All rights reserved.
Source: Journal of Internal Medicine - November 23, 2014 Category: Internal Medicine Authors: A. Emami‐Riedmaier, E. Schaeffeler, A. T. Nies, K. Mörike, M. Schwab Tags: Review‐Symposium Source Type: research